Vilin Bio Med share price: NSE data, merger 2026

Price check: latest reported levels on NSE

Vilin Bio Med’s share price was reported at ₹58.95, with a previous close of ₹57.85 as of 10-09-2026. The same data set shows a day range between ₹56.80 and ₹59.35. A separate market snapshot also shows the counter trading at ₹56.80, down ₹2.95 (-4.94%) at 9:16 AM on 9 September 2026 on NSE: VILINBIO. Another quote line in the source mentions ₹56.05 / ₹59.00 as a range, indicating multiple point-in-time price prints across different updates.

For investors tracking the stock, the key takeaway is that all these figures place the scrip near its recent highs, with the 52-week range stated as ₹18.95 to ₹60.95. The stock is listed on the National Stock Exchange (NSE) and trades under the symbol VILINBIO.

Intraday swing and 52-week band

The intraday movement described in the dataset is meaningful because the stock traded close to the top of its stated daily range. On 10-09-2026, the session range was ₹56.80 to ₹59.35, while the 52-week high was listed as ₹60.95. That puts the stock within a narrow distance of the annual peak based on the provided numbers.

The same dataset also mentions that the stock’s 52-week high and low were ₹59.75 and ₹18.95, respectively, in another snapshot. Since both sets appear in the supplied text, readers should note that the annual high is presented as ₹60.95 in one place and ₹59.75 in another, likely reflecting different timestamps or data vendor rounding.

A data anomaly: “₹0” print in one snapshot

One line in the provided text states: “As of 09-09-2026 14:04, Vilin Bio Med Ltd. share price today is ₹0, with a change of ₹-59.75 (-100.00%) from the previous close of ₹59.75.” The same block also states that the stock opened at ₹60.95 and traded between ₹56.8 and ₹60.95, with total traded volume of 12,000 shares.

Because the source contains both a “₹0” value and a normal trading range for the same date, the “₹0” figure appears inconsistent with the rest of the snapshot. Without additional confirmation beyond the provided text, it is best treated as a data display issue rather than a trading conclusion.

Market capitalisation and valuation metrics cited

The dataset places Vilin Bio Med in the Pharmaceuticals & Biotechnology sector and provides a market capitalisation of ₹86.8 crore. It also lists valuation markers including a P/E ratio of 45 and book value of ₹3.10.

These figures, combined with the stock trading near the upper end of its stated 52-week range, frame the counter as one where corporate developments and liquidity updates can materially influence market perception.

Shareholding trend: promoter holding down, public up

The provided shareholding table shows promoter and public shareholding changes across quarters:

• Promoter holding: 63.9% (Mar 2025), 63.9% (Jun 2025), 63.9% (Sep 2025), 63.6% (Dec 2025), 59.6% (Mar 2026), 56.6% (Jun 2026)
• Public holding: 36.1% (Mar 2025), 36.1% (Jun 2025), 36.7% (Sep 2025), 36.4% (Dec 2025), 40.4% (Mar 2026), 43.3% (Jun 2026)

This indicates a steady decline in promoter stake over the period shown, matched by a corresponding rise in public shareholding.

Chemgenix merger: NSE no-observation letter and next step

A key corporate development mentioned is the company receiving an NSE No-Observation Letter related to the Scheme of Amalgamation of Chemgenix Laboratories Private Limited into Vilin Bio Med Limited. The text notes this as a milestone that allows the company to proceed to the next stage, specifically filing with the Hon’ble NCLT.

A separate corporate announcement summary in the supplied material also states that the board approved the scheme of amalgamation with Chemgenix Laboratories, with a 1:1 share swap, subject to regulatory and shareholder approvals. The combination of these two disclosures indicates that the process is structured and approval-dependent, with the NCLT filing positioned as the next procedural step.

Other corporate development: new wholly owned subsidiaries

The dataset also mentions that Vilin Bio Med planned to incorporate Vilo Speciality Pharma and Axia Pharma as wholly owned subsidiaries, with the update dated Jul 14, 2026. Beyond naming the entities and the wholly owned structure, no additional operational or financial details are provided in the supplied text.

Company profile: what Vilin Bio Med does

Vilin Bio Med Limited engages in the manufacture and trade of pharmaceutical products in India. The company’s product coverage includes segments such as cardiovascular, musculo-skeletal, antibiotic, central nervous system, alimentary system, genito-urinary tract, respiratory system, and anti-allergic and anti-diabetic categories, along with liquid orals and miscellaneous drugs. It also supplies multi-vitamins, minerals, and amino acids supplements.

The company offers multiple dosage forms including oral liquids, dry syrups, sachets, external preparations, beta and non beta lactam tablets and capsules, and nutritional food supplements. It sells products in bulk to pharmaceutical manufacturers, marketers, and traders, and one description states it operates without a brand name. The company was incorporated in 2005, is based in Hyderabad, and one profile note mentions manufacturing operations in Uttarakhand.

Key facts table

Market impact: what changed for investors

From the supplied data, the market-relevant changes are concentrated in two areas: price action near the annual high band and the merger process moving forward procedurally. The stock was reported at ₹58.95 and traded within the ₹56.80 to ₹59.35 range on 10-09-2026, placing it close to the stated 52-week high of ₹60.95. Separately, a 9 September 2026 quote shows ₹56.80 (-4.94%), highlighting that the counter also saw sharp intraday movement.

On the corporate side, the NSE no-observation letter for the Chemgenix scheme and the stated next step of filing with NCLT are concrete milestones in a merger timetable. Since the scheme is described as subject to regulatory and shareholder approvals, investors typically track such events through exchange disclosures and subsequent regulatory outcomes rather than price prints alone.

What to watch next (based on stated events)

The near-term marker mentioned in the text is the company’s move toward filing the merger scheme with the Hon’ble NCLT following the NSE no-observation letter. In parallel, the stock continues to trade within a price zone close to the stated 52-week high band, making day ranges and exchange updates important for short-term tracking.

Separately, investors may also monitor further disclosures linked to the incorporation and operational plans for Vilo Speciality Pharma and Axia Pharma, since the supplied text only confirms the intent to set them up as wholly owned subsidiaries.